Reditus Laboratories

A significant milestone occurred in December 2019 when Reditus Laboratories acquired their first real-time reverse transcriptase polymerase chain reaction (RT-PCR) machine. This cutting-edge technology proved immensely valuable for mass testing the American population for the Covid-19 virus. The acquisition of this machine granted Reditus Labs access to the most sensitive mRNA detection and quantitation technique available.

The company substantially expanded in March 2021 to accommodate its growing operations. The laboratory space was expanded from 2500 sq. ft. to over 23,000 sq. ft., enabling the company to offer anatomic pathology services to diagnose soft tissue and wound infections for various healthcare providers.

Reditus swiftly emerged as a national leader in Covid testing services, having processed over 3.3 million tests and counting. Their laboratory became renowned for offering turnkey solutions to schools, universities, and private industries. Reditus provided on-site training for Covid testing at educational institutions, along with the necessary staff, testing supplies, and kits. Their efforts played a vital role in keeping schools open and ensuring children's health during the worldwide pandemic.

With the capacity to run 100,000 daily tests, Reditus also extended their testing services to government organizations using the ThermoFisher EUA PCR High-throughput testing platform. The company supplied comprehensive test collection kits, which included sterile nasal swabs, transport tubes, and viral collection media, ensuring efficient and accurate testing processes.

The operational efficiency exhibited by the company during its early years stands as a testimony to the exceptional leadership that founded the company. Through the provision of essential personal protective equipment such as glasses, gowns, and masks, as well as accurate testing conducted on a broad range of the local and national population, Reditus made significant contributions to reducing the spread of Covid.